Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-050256

Chief Executive Officer sold 30,000 shares at an average $128.78 ($3,863,469)

  • Chief Executive Officer acquired 30,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2021-08-04 Option exercise +1,500 $12.57 $18,855 189,219 D
Kulkarni Samarth Chief Executive Officer 2021-08-04 Sale −1,500 $125.02 $187,530 187,719 D
Kulkarni Samarth Chief Executive Officer 2021-08-05 Option exercise +28,500 $12.57 $358,245 216,219 D
Kulkarni Samarth Chief Executive Officer 2021-08-05 Sale −1,000 $126.67 $126,670 215,219 D
Kulkarni Samarth Chief Executive Officer 2021-08-05 Sale −4,700 $127.82 $600,754 210,519 D
Kulkarni Samarth Chief Executive Officer 2021-08-05 Sale −13,499 $128.85 $1,739,346 197,020 D
Kulkarni Samarth Chief Executive Officer 2021-08-05 Sale −6,819 $129.82 $885,243 190,201 D
Kulkarni Samarth Chief Executive Officer 2021-08-05 Sale −2,482 $130.51 $323,926 187,719 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2021-08-04 Option exercise · Stock Option (Right to Buy) −1,500 61,833 D
Kulkarni Samarth Chief Executive Officer 2021-08-05 Option exercise · Stock Option (Right to Buy) −28,500 33,333 D
Open-market sales · 30,000 sh · avg $128.78 · $3,863,469
Loading xslF345X03/doc4.xml…